Tercica rhIGF-1 short stature study
This article was originally published in Pharmaceutical Approvals Monthly
Tercica began a Phase IIIb study of its recombinant human insulin-like growth factor-1 (rhIGF-1) in children with short stature caused by primary IGF-1 deficiency Oct. 28. The two-year study, which "will be the basis of a future regulatory filing," will enroll 160 pre-pubertal children whose height and IGF-1 levels are more than two standard deviations below normal. Primary endpoint is change in height SD over one year. Tercica plans to file a separate rhIGF-1 NDA in "early 2005" for severe primary IGF deficiency, a subset of patients whose height and serum IGF-1 levels are more than three standard deviations below normal. Thirty-thousand children have primary IGFD in the U.S., of which 6,000 have the severe form, Tercica estimates...
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.